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ABSTRACT
A sensitive and specific HPLC method was developed and validated for the simultaneous determination of vincamine and its
potential degradant (metabolite), vincaminic acid. Chromatographic separation was achieved on a Spheri-5 RP-C8 (5 μm) (220 ×
4.6 mm i.d.) column using a mobile phase composed of acetonitrile and 0.05 M sodium acetate, pH 4.0 (30 : 70, v/v) at a flow rate
of 1 mL/min. The UV detector was set at 270 nm and the quantitation of the analytes was based on the peak areas. The method was
proven to be accurate and precise with linearity ranges of 0.1 - 50 and 0.4 - 50 µg/mL for vincamine and vincaminic acid, respectively. The limits of detection were 0.03 and 0.08 µg/mL for vincamine and vincaminic acid, respectively. The method was applied
to serve two goals. First; stability-indicating assay of vincamine in its pharmaceutical formulations, in addition, the determination
of vincaminic acid down to a level of 0.07% in presence of excess of the parent drug. Second; drug monitoring of vincamine and its
main metabolite, vincaminic acid in human plasma/urine samples taken from a healthy volunteer treated with 60 mg oral dose of
vincamine. The accuracy of the method was satisfactory (recovery > 97%). The overall standard deviation ranged from 1.4 to 2.3%.
Key words: HPLC, vincamine, vincaminic acid, stability-indicating assay, in-vivo plasma/urine assays

INTRODUCTION
Vincamine (methyl (3α, 16α)-14,15-dihydro-14ßhydroxyeburnamenine-14-carboxylate)(1) is an eburnanetype alkaloid obtained from Vinca minor. It is claimed to
increase cerebral circulation and utilization of oxygen
and has been used in a variety of cerebral disorders (1).
Vincamine (VN) is also one of several active ingredients
in dietary supplements promoted as smart drugs, cognitive enhancers or nootropics. Several methods have been
reported for the determination of VN in pharmaceutical formulations and/or biological samples, including
HPLC(2-9), GC(10-13), TLC(8), fluorimetry(14), spectrophotometry(7,8,15-19), 1H-NMR(20) and adsorptive stripping
voltammetry(21). VN has also been determined in Vinca
minor by TLC(22) and HPLC(23-25) methods.
VN is an ester derivative of eburnamenine nucleus.
* Author for correspondence. Tel: +20-3-4871317;
Fax: +20-3-4871351; E-mail: tbelaleg@yahoo.com

The drug is susceptible to degradation through hydrolysis to yield vincaminic acid (VA)(8). Figure 1 shows the
chemical structures of VN and its hydrolysis product,
VA. Recently, some studies have been interested in developing stability-indicating assays of VN by different
analytical methods. These include derivative-ratio spectrophotometry(8), ratio-subtraction spectrophotometry(15),
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Figure 1. Chemical structures of vincamine (VN) and vincaminic
acid (VA).
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chemometric-assisted spectrophotometry(16), TLC(8) and
HPLC(8). All these methods have been focused on the
determination of VN in the presence of VA. Shehata et
al. reported the selective determination of VN without
interference from VA up to a ratio of 1 : 9 (VN : VA)(8).
However, a major task that the quality control pharmacists face is not only to analyze the intact drug in the presence of its degradation products, but also to determine
the concentrations of the degradation product in bulk
raw material and final pharmaceutical preparations. To
our best knowledge, none of the previous studies handled
this issue. The current study is thus aimed at exploring
the strategy to determine the level of VA in VN drug
substance and pharmaceutical preparations.
In humans, VN is rapidly absorbed after oral administration and metabolized through ester cleavage to VA.
The amount of VN eliminated unchanged in urine is ~
7%. Radiolabel studies on rats(26), after an oral dose of
VN, indicated that VN is hydrolyzed by plasma esterase
to VA. The latter is quickly decarboxylated and oxidized
to eburnamenine. However, apovincaminic acid, the structurally related analogue of VA and the main metabolite of
vinpocetine (semi-synthetic derivative of VN), has been
determined in plasma/urine samples obtained from human
subjects treated with an oral dose of vinpocetine(27,28).
To our knowledge, detection/determination of VA in
human plasma/urine samples has not been reported yet.
Most of the previous research(2-5,11-13) have been interested in the quantification of VN only.
The purpose of the present work was to develop a
simple and reliable RP-HPLC method with UV-detection
for simultaneous determination of VN and its degradant/
metabolite, VA. This was in order to serve three goals:
(I) establishment of a stability indicating assay method
of VN to be applied in pharmaceutical analysis; (II)
determination of VA as a potential degradant/impurity
of VN, in raw material samples and pharmaceutical
formulations; and (III) application to biological analysis;
in-vitro and in-vivo assays of VN and its metabolite, VA
in human plasma and urine samples.

MATERIALS AND METHODS
I. Instrumentation
The HPLC system used was Perkin Elmer Series 200
(USA), equipped with a quaternary pump solvent delivery
system, auto-sampler and UV detector. The system was
operated with TotalChrom Workstation Perkin Elmer Chromatography software. The detector was set at 270 nm.
Photodiode array absorption spectra were acquired with
Agilent 1200 series HPLC system with a multiple wavelength photodiode array detector (PDA). The HPLC
system consisted of a quaternary pump and an on-line
injector equipped with a 50-µL sample loop, and was
operated with Agilent ChemStation Software.

1

H-NMR spectra were recorded on JEOL spectrometer (500 MHz, δ ppm) using DMSO-d 6 as solvent. Mass
spectra were run on Finnigan SSQ/7000 Mass Spectrometer (70 eV, Thermo Electron Corporation). IR spectra
were obtained on a Perkin-Elmer RX I FT-IR system.
II. Chemicals and Reagents
Vincamine standard (98% purity) was purchased
from Sigma-Aldrich. Oxybral® capsules (each labeled
to contain 30 mg of VN) and Oxybral® ampoules (each
labeled to contain 15 mg of VN) were supplied by GlaxoSmithKline S.A.E., Egypt. HPLC-grade acetonitrile was
purchased from Labscan Ltd., Dublin, Ireland. Other
chemicals were all of analytical grade.
III. Chromatographic Conditions and Analysis
Chromatographic separation was performed on
a Spheri-5 RP-C8 column (Perkin-Elmer BrownLee
columns, 220 mm × 4.6 mm i.d., 5 µm particle size). The
column temperature was maintained at 25°C.
Separation was achieved with a mobile phase of acetonitrile - 0.05 M sodium acetate (30 : 70, v/v), adjusted to
pH 4.0 using glacial acetic acid. The flow rate was set at 1.0
mL/min throughout the run and the UV detector was set at
270 nm. The injection volume was 50 µL. The injections
were made in duplicate. The peak areas were measured.
IV. Degradation Reaction, Isolation and Purification of the
Degradation Product, VA
Five hundred milligram of VN was mixed with
20 mL of 3 M HCl and subjected to hydrolysis by heating
in a boiling water bath for 100 min. The resulted solution
was cooled and VA was extracted by 3 × 20-mL portions
of chloroform. The combined chloroform extract was
dried over anhydrous sodium sulphate and evaporated
under vacuum to obtain a solid residue (yellow crystalline
solid). Crystallization was carried out using methanol.
V. General Procedure
Standard stock solutions of VN (reference substance)
and VA (isolated and purified substance), 400 µg/mL each,
were prepared in methanol and kept in the refrigerator.
The solutions were stable for at least two days. Working
standard solutions with the concentration ranges of
0.1 - 50 µg/mL and 0.4 - 50 µg/mL for VN and VA,
respectively, were prepared by dilution of aliquots of the
stock solutions with the mobile phase.
VI. Preparation of Assay Solutions from Capsules/Ampoules
To an accurately weighed quantity of the mixed
powdered content of Oxybral® capsules, equivalent to
40 mg of VN, 50 mL of methanol were added and stirred
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VII. Assay Solutions for the Determination of VA at Trace
Level in VN
Using a set of 10-mL volumetric flasks, working
standard solutions of VN were prepared to attain a
final concentration range of 5-1000 µg/mL, taking into
consideration that such solutions were spiked with VA at
different levels (within 10 to 0.05%). The volumes were
made up to 10 mL with the mobile phase.
VIII. Preparation of Plasma/Urine Samples
Frozen plasma/urine was thawed at room temperature. Separate 1-mL aliquots of plasma/urine were transferred into a set of centrifuge tubes and spiked with suitable amounts of standard VN and VA solutions to cover
the concentration range of 0.02 - 0.5 and 0.08 - 1.0 µg/mL
for VN and VA, respectively. Protein precipitation was
carried out with 1 mL of ethanol, followed by centrifugation for 15 minutes at 4000 rpm. The supernatant of
each prepared sample was evaporated to dryness with
nitrogen. Separate residues were reconstituted in 200 µL
of mobile phase. The same sample handling process was
carried out for the linearity, recovery, precision, accuracy
and stability tests.
IX. Preparation of In-vivo Samples and Pharmacokinetic
Study
The method was applied to determine the concentrations of VN and its metabolite, VA, in the plasma/urine
samples from a healthy subject, who was treated by a
single 60-mg oral dose of VN sustained-release capsules.
Venous blood samples were drawn before dosing (0 h)
and at 0.5 h, 1 h, 2 h, 3 h, 4 h, and 6 h, after dosing. All
blood samples were collected in heparinized tubes and
centrifuged at 4000 rpm immediately. The separated
plasma samples were stored at -20°C until analysis.
Urine samples were collected before dosing (0 h) and at
2 h intervals, up to 8 h and stored at -20°C until analysis.
One milliliter aliquot of thawed plasma/urine samples
was processed as described in Section VIII above.

RESULTS AND DISCUSSION
I. Aspects Concerning Hydrolysis of VN
Previous studies(8,15) on VN hydrolytic degradation
indicated that the reaction is acid-catalyzed. The degradation product, vincaminic acid (VA), has been isolated and
structurally confirmed by MS analysis. As described in
these studies(8,15), hydrolysis was achieved under stress
conditions of 2 M HCl/100°C for 7 h. To our knowledge, no
study on the kinetics of the degradation, pH-degradation
rate profile or the effect of mild conditions of temperature,
moisture, etc. has been reported.
In the present work, the reaction time was reduced at
the expense of acid strength. Three hydrolysis reactions
were carried out in 2, 3 and 4 M HCl, at 100°C followed
by the chromatographic measurement of the degradation
product, VA, which eluted at 5.06 min under the conditions described above. The results indicated that the
degradation in 3 M HCl/100°C for 100 min, is adequate
for complete hydrolysis (Figure 2). Hence, the degradation product, VA, was prepared and isolated as described
in Materials and Methods Section IV.
The structure of the isolated product, VA, was confirmed
by IR, 1H-NMR, MS spectroscopy and elemental analysis.
All criteria have assigned the structure to be (3α, 16α)-14,15dihydro-14ß-hydroxyeburnamenine-14-carboxylic acid.
The IR spectrum (KBr disk) of VA refers to C = O and OH
stretching bands at 1662 cm-1 and 3300 cm-1, respectively. The
IR spectrum (KBr disk) of VN shows the characteristic ester
C = O band at 1749 cm-1 while the OH band is missing.
The 1H-NMR spectrum of VA (DMSO, δ ppm, 500
MHz) showed the following characteristic signals: 0.94
(t, 3H, J = 7.7 Hz, CH 2-CH 3), 1.46-1.50 (m, 2H, C18 -H),
1.79 (q, 2H, J = 7.7 Hz, CH 2-CH 3), 1.87 (s, 2H, C15 -H),
1.88-1.93 (m, 2H, C17-H), 2.00-2.10 (m, 2H, C6 -H), 2.903.11 (m, 4H, C5,19 -H), 3.9 (s, 1H, C3 -H), 4.7 (s, 1H, OH),
7.11(t, 1H, J = 7.6 Hz, C10 -H), 7.18 (d, 1H, J = 8.4 Hz,
C9 -H), 7.3 (d, 1H, J = 8.4 Hz, C12-H), 7.52 (t, 1H, J = 7.0
Hz, C11-H) and 11.3 (broad s, 1H, COOH).

HPLC response, peak area x 105

for 10 min followed by filtration through 0.45-µm Millipore membrane filter into a 100-mL volumetric flask.
The residue was washed with two 10-mL portions of
methanol and the washings were added to the filtrate and
diluted to volume with methanol. The resulting solution
contained 400 µg/mL of VN. Working assay solutions
were prepared by suitable dilutions with methanol.
An accurate volume of the mixed contents of five
Oxybral® ampoules, equivalent to 40 mg of VN, was
transferred into a 100-mL volumetric flask, mixed and
diluted to volume with methanol. The resulting solution
contains 400 µg/mL of VN. Working assay solutions
were prepared by suitable dilutions with methanol.
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Figure 2. Reaction time course of the hydrolysis of VN (1.0 µg/mL)
at 100°C.
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The MS spectrum showed diagnostic fragment
ions m/z 322, (M+ -H 2O, C20H 22N2O2 , 53.8%), m/z 293
(C18H17 N2O2 , 90.0%), m/z 248 (C17 H16 N2 , 18.8%),
m/z 206 (C14H10N2 , 43.8%), m/z 193 (C13H9N2 , 30.0%),
m/z 180 (C12H8N2 , 18.8%), m/z 154 (C11H8N, 17.5%) and
m/z 128 (C10H8, 10.0%).
Finally, elemental analysis of VA (molecular
formula C20H 24O3N2 , Mr 340.40) obtained the percentages, 70.40% and 7.49% for C and H, respectively. The
calculated percentages are 70.57% and 7.11% for C and
H, respectively.
II. Method Development and Optimization of Chromatographic Conditions
Several HPLC methods have been reported for
the determination of VN, especially in biological
f luids (2-5) and for the separation and determination of
VN in combination with piracetam (6,7). To our knowledge, only one stability-indicating HPLC assay (8) has
been recently reported for the determination of VN
in the presence of its hydrolytic product, VA, using a
C18-column and mobile phase composed of acetonitrile

2.55

1

: 0.01 M ammonium carbonate (70 : 30, % v/v). These
chromatographic conditions allowed for good separation. However, VN was eluted at a short retention time
of 3.6 min.
The present work aimed to develop a RP/HPLC/
UV method suitable for the simultaneous determination
of VN and VA, which would be of potential importance
in monitoring VN and its metabolite, VA in biological
fluids, such as plasma and urine. Accordingly, the chromatographic conditions were investigated to achieve
effective separation of VN/VA with adequate retention
and to assure resolution from plasma/urine interfering
peaks.
The chromatographic conditions, especially the
composition of the mobile phase (pH and % organic
modifier) were optimized. A mobile phase system
consisting of acetate buffer and acetonitrile was tested.
The effects of acetonitrile content (within 30 to 70%, v/v)
and the pH (ranging from 3 to 7) of the acetate buffer
on the chromatographic performance were investigated
using a standard mixture of VN and VA (1 µg/mL each).
The study indicated that a mobile phase consisting of
30% acetonitrile offered the best chromatographic resolution and column efficiency, and advantageously, appropriate retention of VN and VA was obtained with elution
times of 7.15 and 5.06 min, respectively.
Although, apparently, pH 7 offers the best resolution and column efficiency, VA is eluted quickly with
a retention time of 3.71 min. A mobile phase of pH 4
provided the best retention of VA (retention time of
5.06 min) with suitable resolution, column efficiency and
peak symmetry. Accordingly, a mobile phase of pH 4 was
chosen as the most appropriate for the current study. A
typical chromatogram for the separation of VN and VA
using the proposed procedure is shown in Figure 3.

1.52

III. Method Validation

mV

2

The method was validated according to the International Conference on Harmonization (ICH) Q2 (R1)
requirements (29). The following validation parameters
were addressed: system suitability, linearity, range, accuracy, precision, specificity, limits of detection and quantification, solution stability and robustness.

0.49

(I) System Suitability

-0.54
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Figure 3. Typical chromatogram of a 50-µL injection of a standard
mixture of (1) 1 µg/mL VA and (2) 1 µg/mL VN.

System suitability tests were performed to verify
the HPLC system performance. The system suitability
parameters include retention time, capacity factor, tailing
factor, resolution and number of theoretical plates. The
system precision was also assessed based on the relative
standard deviation (% RSD, n = 6) of the retention times
and peak areas of the working standards. The results are
listed in Table 1. The system suitability parameters were
within the acceptable limits.
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(II) Linearity

(III) Specificity

The linearity range of the HPLC method for determining VN and VA was evaluated by analyzing a series
of standards (n = 8) over the concentration levels of
0.1 - 50 and 0.4 - 50 µg/mL, respectively. Table 1 assembles the analytical performance data, including regression
equations computed from calibration graphs, concentration ranges, correlation coefficients along with the
standard deviation of the intercept (Sa), the slope (Sb),
the standard deviation of residuals (Sy/x) and percentage
relative standard deviation of the slope (Sb, %). Correlation coefficient values (> 0.9995) indicated good linearity.
Additionally, percentage relative standard deviations of
the slope (Sb %) were found to be less than 1.2%.

The specificity of the developed HPLC method for
the determination of VN and/or VA in bulk drug, pharmaceutical preparations and plasma/urine samples was
investigated by chromatographic analysis of the following:
(1) standard solutions of VN and VA, the specificity was
proven by the absence of mutual interference of the eluted
chromatographic peaks, i.e. the peak eluted at the retention time, 7.15 min was selective for VN measurement and
5.06 min for VA measurement (Figure 3); (2) a solution
of co-formulated adjuvants commonly used in sustainedrelease capsules (hydroxypropylmethylcellulose, sodium
carboxymethylcellulose and magnesium stearate), the
chromatogram of this solution showed no peak throughout
the run time of the HPLC method; (3) assay solutions of
the capsules and ampoules, the chromatograms of these
solutions showed a single peak at 7.15 min due to VN and
the spiking of the VN standard into these test solutions
resulted in an increase of the peak area at 7.15 min; (4)
solutions of treated-drug-free human plasma/urine control
samples, the chromatograms of these solutions showed
no interfering peaks eluted at/or near the retention times
of either VN or VA; (5) solutions of human plasma/urine
control samples spiked with VN and VA, the chromatograms of these solutions showed two peaks at 5.06 and
7.15 min for VA and VN, respectively, i.e. no variation was
observed in their respective retention times, indicating the
selectivity of measurements (Figures 4 and 5).

Table 1. Analytical parameters for the proposed HPLC method
VN

VA

Capacity factor

2.71

1.61

Number of theoretical plates

1202

5265

Asymmetry

2.18

1.40

System suitability parameters

Resolution

3.3

Repeatability-tRa

0.78

1.78

Repeatability-Aa

0.88

0.64

0.1 - 50

0.4 - 50

a ± Sab

-8890 ± 16200

225 ± 391

b ± Sbc (Sb %)d

75200 ± 850.05
(1.13)

20300 ± 19.38
(0.10)

0.9995

0.9998

99.2 (1.9)

100.0 (1.8)

Validation
Concentration range (µg/mL)
Regression data (n = 8)

r
Accuracy and Precision
Mean % recovery e (% RSD)
f

Mean % recovery (% RSD)

101.2 (1.2)

g

0.03

0.08

LOQ (µg/mL) h

0.09

0.25

LOD (µg/mL)
a

% RSD calculated for six replicates for retention time, tR and peak
area, A.
b
Standard deviation of the intercept.
c
Standard deviation of the slope.
d
Percentage relative standard deviation of the slope.
e
Mean of five determinations of standard mixtures prepared in VN/
VA ratios of 1 : 1 to 1 : 25 at three concentration levels.
f
Mean of five determinations of VA added to capsule simulated
solution at three concentration levels (1 - 5 µg/mL).
g
Limit of detection.
h
Limit of quantification.

(IV) Accuracy and Precision
The accuracy and precision of the developed HPLC
method for the determination of VN and/or VA in bulk
drug, pharmaceutical preparations and plasma/urine
samples were assessed by assays of five determinations
over three concentrations covering the specified working
range. The first assay involved simultaneous determinations of VN and VA in standard synthetic mixtures
within the concentration ranges of 0.1 - 0.5 µg/mL VN and
0.5 - 5.0 µg/mL VA in ratios 1 : 1 to 1 : 25 VN/VA. In the
second assay, VA added in known amounts (1 - 5.0 µg/mL)
to formulation excipients (hydroxypropylmethylcellulose,
sodium carboxymethylcellulose and magnesium stearate)
was measured. The accuracy (% recovery) and precision
(RSD %) of the method are given in Table 1. All data indicated that the method was highly accurate and precise for
the determination of VN and/or VA and no interference
was found from the excipients in the formulation. The
results implied that VN can be selectively determined in
the presence of VA, with good accuracy and precision, up
to a ratio of 1 : 25 (VN : VA). The third assay employed the
chromatographic analysis to human plasma/urine samples,
which were spiked with standard VN and VA over the
concentration ranges of 0.02 - 0.5 and 0.08 - 1.0 µg/mL,
respectively. The absolute recoveries of VN and VA were
calculated according to the calibration data of standard
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solutions. The % recovery ranged from 98 to 102% and
from 99 to 102% for VN and VA, respectively and the
precision (overall SD) ranged from 1.4 to 1.8 and from 1.6
to 2.3, for VN and VA, respectively (Table 2).
(V) Limits of Detection and Quantification
The limits of detection (LOD) and quantification
(LOQ) were determined at signal to noise ratios of 3 : 1
and 10 : 1, respectively. The data are given in Table 1.
(VI) Robustness
The robustness of the proposed HPLC method
was tested by investigating the effect of slight variations in the mobile phase (% acetonitrile and pH) on the

capacity of the column to retain and resolve VN and VA.
Changing the pH of the mobile phase by ± 0.1 pH unit or
% acetonitrile by ± 2% (v/v) did not significantly affect
the chromatographic performance (k′ and resolution).
The % RSD of the measured peak areas after the studied
variations did not exceed 2%.
(VII) Stability Tests
The stability of standard solutions of VN and VA in
methanol, after storing at 4◦ C for 48 hours, was examined using chromatographic measurements. The recoveries were within 98 to 102%. Freeze-thaw stability was
assessed by subjecting plasma/urine samples, spiked
with VN/VA at a concentration of 1 µg/mL to three
freeze-thaw cycles. Each cycle consisted of removing

Table 2. Accuracy and precision for the HPLC assay of spiked plasma and urine samples
VN
Spiked (μg/mL)

VA
a

Mean % Recovery ± SD

Spiked (μg/mL)

Mean % Recoverya ± SD

Plasma samples
0.02

97.92 ± 1.4

0.08

99.9 ± 2.8

0.05

97.9 ± 1.3

0.2

101.2 ± 2.2

0.1

101.7 ± 1.4

0.4

99.1 ± 1.5

0.2

97.7 ± 0.7

0.8

101.0 ± 2.3

0.5

100.9 ± 2.1

1.0

98.9 ± 2.5

Grand mean (% Recovery): 99.2

Grand mean (% Recovery): 100.0

Overall SD: 1.4

Overall SD: 2.3

SAE: 0.32

SAE: 0.51

Confidence Limit: 0.57

Confidence Limit: 0.89

Accuracy: 99.2 ± 0.57

Accuracy: 100.0 ± 0.89

Urine samples

a

0.02

100.2 ± 2.0

0.08

101.6 ± 1.6

0.05

99.3 ± 2.7

0.2

98.2 ± 1.6

0.1

100.1 ± 1.2

0.4

99.9 ± 2.2

0.2

100.4 ± 1.6

0.8

102.1 ± 1.2

0.5

102.1 ± 1.2

1.0

101.0 ± 1.2

Grand mean (% Recovery): 100.4

Grand mean (% Recovery): 100.6

Overall SD: 1.8

Overall SD: 1.6

SAE: 0.4

SAE: 0.4

Confidence Limit: 0.71

Confidence Limit: 0.62

Accuracy: 100.4 ± 0.71

Accuracy: 100.6 ± 0.62

Mean % recovery of five determinations.
SAE: Standard analytical error.
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the samples from the freezer, thawing them unassisted
to room temperature, keeping at room temperature for
2 h and re-freezing at -20°C. The stability experiment
confirmed that plasma/urine samples were stable through
three freeze-thaw cycles.
IV. Applications
(I) Determination of VA (Degradation Product/Impurity) at
Trace Level in VN
The validated HPLC method was applied for the
determination of VA at trace levels in VN. The mean
% recoveries of VA ranged from 98 to 102% (% RSD
ranged from 0.8 to 1.3) at starting levels at 10% down to
0.07% (w/w).
(II) Analysis of Commercial Dosage Forms
The proposed HPLC method was applied for the
determination of VN in commercial dosage forms,
including capsules and ampoules. The methods gave
satisfactory precision and recovery data, which were
in good agreement with the label claims (Table 3). The
results were compared statistically with those obtained
by the reported derivative ratio spectrophotometric
method (8) using Student’s t-test and the F-variance ratio
test at 95% confidence level (Table 3). There was no
significant difference between the calculated and theoretical values at p = 0.05, demonstrating that the proposed
method was as accurate and precise as the reported one.
(III) Detection of VA, Degradation Product/Impurity, in
Oxybral® Capsules and Ampoules
The proposed HPLC method was applied for the
detection/determination of VA in VN commercial

Table 3. Assay results for the determination of VN in pharmaceutical preparations
Preparations

% Recoverya (% RSD)
HPLC Method

Oxybral® capsulesc

99.94 (1.2)
t = 0.60 , F = 1.07e

Oxybral® ampoulesd

100.4 (0.4)
t = 1.14 , F = 2.4e

a

Reference Methodb
99.5 (1.3)

100.0 (0.6)

Mean % recovery of five determinations.
Reference (8).
c
Oxybral® capsules were labeled to contain 30 mg of VN per
capsule.
d
Oxybral® ampoules were labeled to contain 15 mg of VN per 2
mL.
e
Tabulated t-value for p = 0.05 and 8 degree of freedom is 2.306;
tabulated F-value for p = 0.05 and f1 = f 2 = 4 is 6.38.
b

capsules and ampoules. Solutions of Oxybral® capsules
and ampoules were prepared at concentrations ranging
from 100 to 1000 µg/mL VN and analyzed for VA
content. The results of analysis referred to the presence
of VA at a level of 0.075 % (w/w) in Oxybral® capsules.
No VA was detected in Oxybral® commercial ampoules.
(IV) Applications to Human Plasma and Urine Samples
The detection/determination of VA in human
plasma/urine samples has not been reported yet. Most
of the previous researches have been focused on the
quantification of VN only and are based on the extraction clean-up procedure which separates VN only rather
than its metabolite, VA. Several HPLC(2-5) and GC(1113)
methods have been reported for the determination of
VN in plasma samples. Of the most important points,
concisely mentioned were the following: the analytical
sensitivity for the determination of concentrations as
low as 5 ng/mL VN spiked into control plasma samples
has been achieved(2,3); few studies have been interested
in the analysis of plasma samples collected from volunteers treated with VN(2,4,11); treatment of plasma samples
has been based on tedious extraction procedure involving
one, two (2) or even three steps(11); and none of these
studies discussed the interference/or determination of
VN′s metabolites.
The present work was primarily focused on the
employment of the validated HPLC method for the
determination of VN and its metabolite, VA, in biological samples (plasma/urine). The specificity, accuracy
and precision of the HPLC method had been verified by
spiking experiments discussed above (Table 2).
Sample pre-treatment included a clean-up step of
protein deposition by ethanol. This was particularly
simple, easy to handle and allowed for fast analysis.
Moreover, both VN and VA could be measured
simultaneously without a tedious extraction procedure.
Preliminary experiments were carried out to choose the
working solvent, which can be used as a deproteinizing
agent of plasma and urine samples. Acetonitrile, methanol
and ethanol were examined, of which ethanol was selected
as the most appropriate as it showed the maximum %
recovery values, as compared to standards containing the
same theoretical concentration of the compound being
analyzed. The clean-up step, in addition to the appropriate
chromatographic conditions, allowed for adequate
separation and resolution of VN and VA peaks from
plasma/urine peaks (Figures 4 and 5). Furthermore, the
reconstitution of residue, obtained from 1 mL of plasma/
urine, in 200 µL of mobile phase permitted a pre-concentration step (5-fold). This improved the sensitivity of the
quantification of VN and VA to concentration levels of 20
and 80 ng/mL, respectively.
Although the absorptivities of VN and VA at 225 nm
is ~ 2-3 folds higher than that at 270 nm, the latter was
chosen as the most appropriate for the present work as it
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Oxybral® capsules (each labeled to contain 30 mg of
VN). The concentrations of VN and VA were calculated with reference to the calibration data by peak area
measurements. Only VN was observed in the plasma
samples. The peak plasma concentration was 102 ng/mL

minimized the interference of plasma/urine peaks during
VA determination. The % recovery of VA in plasma/urine
might reach 130% if 225 nm was chosen for detection.
Plasma/urine samples were taken from a healthy
human subject after the oral administration of two
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Figure 4. Typical chromatograms of (A) control plasma, (B) plasma sample spiked with VA and VN (1 µg/mL, each) and (C) plasma obtained
from the volunteer at 2 h after oral administration of 60 mg of VN. 1 = VA; 2 = VN.
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Figure 5. Typical chromatograms of (A) control urine, (B) urine sample spiked with VA and VN (1 µg/mL, each) and (C) urine obtained from
the volunteer at 4 h after oral administration of 60 mg of VN. 1 = VA; 2 = VN.
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Figure 6. (A) Plasma concentrations and (B) Log plasma concentrations of VN after oral administration of two Oxybral ® capsules (60 mg of
VN).

Table 4. The amounts of VN and its metabolite (VA) found in
the urine of a healthy volunteer after oral administration of two
Oxybral® capsules
Time (h)

Amount of VN
excreted (µg)

Amount of VA
excreted (µg)

2

1.1

1.5

4

3.6

5.9

6

3.7

9.3

8

3.4

11.1

at 2 h. Figure 6A displays the profile of plasma concentration of VN versus time. The elimination constant, K′,
derived from the log plot (Figure 6B) was found to be
0.18 h-1, and accordingly, the half life time of VN was
3.85 h. The data obtained was closely related to that
reported on sustained-release formulations (11). Both VN
and VA were observed in the urine samples. The amounts
of VN and VA excreted were listed in Table 4.
Figure 4 displays the chromatograms of (A) control
plasma, (B) control plasma sample spiked with VN
and VA, 1 μg/mL each, and (C) plasma sample taken
at 2 h. No signal appeared in the blank plasma at the
retention times of VN and VA (A). Also, the chromatographic peaks of VN and VA, spiked into plasma sample
(B) appeared at the same retention times as those of
standards. Analysis of plasma sample collected at 2 h
revealed the VN peak only. Figure 5 shows the chromatograms of (A) control urine, (B) control urine sample
spiked with VN and VA, 1 μg/mL of each, and (C) urine
sample collected at 4 h. No signal appeared in the blank
urine at the retention times of VN and VA (A). Also, the

chromatographic peaks of VN and VA spiked into urine
sample (B) showed the same retention times as those
of standards. Analysis of urine sample collected at 4 h
revealed both VN and VA peaks.
The identity of VA (metabolite) observed in urine
samples was confirmed through peak enrichment in the
spiking experiments of the assay solution (urine) with
VA standard. No shift in the retention time was observed.
Moreover, confirmation of the identity of VA was done
using HPLC-system coupled with photodiode array
detector to supply the absorption UV spectra for the peaks
eluted for VA standard solution and urine assay solution.
Figure 7 displays the photodiode array absorption spectra
of VA standard solution and urine assay solution. The
wavelengths of the absorption maxima and minima were
identical for both. This finding confirmed the identity of
VA as a metabolite of VN, excreted in human urine.

CONCLUSIONS
The HPLC method established in this work
provided a simple, specific, accurate and precise way for
determining VN and/or VA. Being a separation method,
the developed procedure presented selectivity advantage
over non-selective spectrophotometric stability-indicating reports for VN(8,15,16). For the linearity ranges,
the proposed method was more sensitive and reliable
than the previous stability-indicating methods (8,15,16).
The proposed HPLC method provided a worthy addition to the scientific literature of VN in view of the
following points: (a) direct and fast analysis, (b) it offers
advantageous application in monitoring and simultaneous determination of VN and VA in human plasma/
urine samples, following a simple and fast sample cleanup step. No analytical method has been reported for the
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Figure 7. (1) Absorption spectra of standard VA solution and (2)
urine assay solution after 4 h obtained by HPLC system coupled with
photodiode array detector.

determination of VA in human plasma/urine samples
(in-vivo), (c) the identity of VA, as a metabolite of VN
observed in human urine samples, was confirmed using
UV spectra acquired by HPLC-photodiode array system,
(d) determination of VA as an impurity/degradant in VN
samples down to 0.07% level, and (e) the proposed procedure was validated and proved suitable for the estimation
of VN in commercial pharmaceutical formulations.
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